---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056175"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:51:32.009878+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q3 revenue $29.9M (+16% YoY); net loss $35M vs $3.9M income; lowers drug discovery revenue guidance

## Summary
- Revenue $29.9M (+16% YoY); software revenue $24.3M (+6%), drug discovery $5.6M (up from $2.9M).
- Net loss $35.0M vs net income $3.9M in Q3 2020; operating expenses rose to $45.8M from $30.7M.
- Cash and marketable securities $600.2M as of Sep 30, 2021, down from $616.6M at Jun 30.
- Full-year drug discovery revenue guidance revised to $22-24M from $22-32M; software guidance maintained at $102-110M.
- Selected development candidate for CDC7 inhibitor; MALT1 IND submission expected H1 2022; pipeline expanded to five programs.

## SEC filing metadata
- accession: 0001564590-21-056175
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000156459021056175/0001564590-21-056175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000156459021056175/sdgr-8k_20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056175
- JSON: https://secwatch.observer/filing/0001564590-21-056175.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.